ASKA PHARMACEUTICAL CO., LTD. Inactive Instrument
ASKA Pharmaceutical Co., Ltd. Stock Japan Exchange
Equities
4514
JP3541200006
Pharmaceuticals
| Sales 2025 * | 64.02B 406M | Sales 2026 * | 67.79B 429M | Capitalization | 68.59B 434M |
|---|---|---|---|---|---|
| Net income 2025 * | 5.24B 33.21M | Net income 2026 * | 5.24B 33.16M | EV / Sales 2025 * | 0.88 x |
| Net cash position 2025 * | 12.31B 77.97M | Net cash position 2026 * | 17.19B 109M | EV / Sales 2026 * | 0.76 x |
| P/E ratio 2025 * |
13.1
x | P/E ratio 2026 * |
13.1
x | Employees | 762 |
| Yield 2025 * |
2.07% | Yield 2026 * |
2.11% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| President | 72 | 21-03-31 | |
Kiyohiko Tamura
ADM | Chief Administrative Officer | - | - |
Kunihiro Gunji
CMP | Compliance Officer | - | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| President | 72 | 21-03-31 | |
Atsushi Maruo
BRD | Director/Board Member | 65 | 21-03-31 |
| Director/Board Member | 75 | 21-03-31 |
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.
Sector
Pharmaceuticals
Calendar
2024-08-04
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +62.66% | 854B | |
| +40.42% | 636B | |
| -4.37% | 361B | |
| +17.16% | 324B | |
| +9.87% | 301B | |
| +15.66% | 247B | |
| +17.90% | 228B | |
| +14.86% | 177B | |
| +0.45% | 164B |
